Business
Ludwig Enterprise mRNA Program Generating Broad Clinical Interest
Ludwig Enterprise mRNA Program Generating Broad Clinical Interest.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"SPARKS, NV / ACCESSWIRE / March 14, 2023 / Ludwig Enterprises, Inc. (Ludwig - The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index™ which measures inflammatory biomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease. To date Precision Genomics has collected and is testing over 1700 samples from 28 different medical clinics along with detailed patient medical history. The company is receiving over 100 samples each month.The World Health Organization estimates that 50% of the world's deaths are due to illnesses that have inflammation as a causation, including diabetes, COPD, heart disease and various cancers."The mRNA Inflammatory Index™ is unique," says its creator Marvin S. Hausman MD. "A person's inflammatory snapshot is created at a specific point in time in a disease process. This inflammatory index has the potential to guide doctors in their patient treatment program."The global mRNA therapeutics market is estimated to be $39.9 billion and is expected to continue to grow 1.7% annually until 2030. "This market growth is fueled by the rising prevalence of chronic diseases like cancer, heart disease, respiratory, CKD, and rare diseases," reported Grandview Research. You can view their report at https://www.grandviewresearch.com/industry-analysis/mrna-therapeutics-market-report."While we still need additional data and are not ready to publish, our research is generating some very promising results," added Dr. Hausman. "I am particularly excited about early results that could reveal mRNA genetic differences between breast, colon and bladder cancer."Ludwig Enterprises has IRB approval for a study using the mRNA Inflammatory Index to possibly identify early detection of bladder cancer and early detection of bladder cancer recurrence. The company also has an agreement to support the Ketamine Clinic industry to confirm outcomes for patients with Treatment Resistant Depression and is also exploring opportunities with groups focused on treating diabetes and obesity."Ludwig Enterprises is open to exploring opportunities with organizations conducting research into mRNA therapeutic vaccines and pharmaceuticals," said ...